About the Study

Leukemia & Lymphoma: A study of tagraxofusp with or without chemotherapy in pediatric patients with relapsed or refractory CD123 expressing hematologic malignancies

This study is for: • Patients who are between the ages of 1 and 21 years old • Who have been diagnosed with a hematologic maligancy (including, but not limited to acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome, mixed phenotype acute leukemia, acute undifferentiated leukemia, blastic plasmacytoid dendritic cell neoplasm, Hodgkin lymphoma, and non-Hodgkin lymphoma) that has relapsed (has come back) or is refractory (has not responded to earlier treatment). • The cancer also must have a specific protein present called CD123 The goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to find the effects, both good and/or bad, tagraxofusp has in pediatric patients.

Interested in learning more?

Full Study Name: T2020-006